Mining the fecal proteome

from biomarkers to personalised medicine

Ping Jin, Kui Wang, Canhua Huang, Edouard C. Nice

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Introduction: Fecal proteomics has gained increased prominence in recent years. It can provide insights into the diagnosis and surveillance of many bowel diseases by both identifying potential biomarkers in stool samples and helping identify disease-related pathways. Fecal proteomics has already shown its potential for the discovery and validation of biomarkers for colorectal cancer screening, and the analysis of fecal microbiota by MALDI-MS for the diagnosis of a range of bowel diseases is gaining clinical acceptance. Areas covered: Based on a comprehensive analysis of the current literature, we introduce the range of sensitive and specific proteomics methods which comprise the current ‘Proteomics Toolbox’, explain how the integration of fecal proteomics with data processing/bioinformatics has been used for the identification of potential biomarkers for both CRC and other gut-related pathologies and analysis of the fecal microbiome, outline some of the current fecal assays in current clinical practice and introduce the concept of personalised medicine which these technologies will help inform. Expert commentary: Integration of fecal proteomics with other proteomics and genomics strategies as well as bioinformatics is paving the way towards personalised medicine, which will bring with it improved global healthcare.

Original languageEnglish
Pages (from-to)445-459
Number of pages15
JournalExpert Review of Proteomics
Volume14
Issue number5
DOIs
Publication statusPublished - 4 May 2017

Keywords

  • big data
  • Biomarkers
  • colorectal cancer
  • fecal proteomics
  • HUPO
  • mass spectrometry
  • microbiota
  • personalised medicine

Cite this

Jin, Ping ; Wang, Kui ; Huang, Canhua ; Nice, Edouard C. / Mining the fecal proteome : from biomarkers to personalised medicine. In: Expert Review of Proteomics. 2017 ; Vol. 14, No. 5. pp. 445-459.
@article{4bc64a61711649a5a4481adb8fa8ff58,
title = "Mining the fecal proteome: from biomarkers to personalised medicine",
abstract = "Introduction: Fecal proteomics has gained increased prominence in recent years. It can provide insights into the diagnosis and surveillance of many bowel diseases by both identifying potential biomarkers in stool samples and helping identify disease-related pathways. Fecal proteomics has already shown its potential for the discovery and validation of biomarkers for colorectal cancer screening, and the analysis of fecal microbiota by MALDI-MS for the diagnosis of a range of bowel diseases is gaining clinical acceptance. Areas covered: Based on a comprehensive analysis of the current literature, we introduce the range of sensitive and specific proteomics methods which comprise the current ‘Proteomics Toolbox’, explain how the integration of fecal proteomics with data processing/bioinformatics has been used for the identification of potential biomarkers for both CRC and other gut-related pathologies and analysis of the fecal microbiome, outline some of the current fecal assays in current clinical practice and introduce the concept of personalised medicine which these technologies will help inform. Expert commentary: Integration of fecal proteomics with other proteomics and genomics strategies as well as bioinformatics is paving the way towards personalised medicine, which will bring with it improved global healthcare.",
keywords = "big data, Biomarkers, colorectal cancer, fecal proteomics, HUPO, mass spectrometry, microbiota, personalised medicine",
author = "Ping Jin and Kui Wang and Canhua Huang and Nice, {Edouard C.}",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14789450.2017.1314786",
language = "English",
volume = "14",
pages = "445--459",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Taylor & Francis",
number = "5",

}

Mining the fecal proteome : from biomarkers to personalised medicine. / Jin, Ping; Wang, Kui; Huang, Canhua; Nice, Edouard C.

In: Expert Review of Proteomics, Vol. 14, No. 5, 04.05.2017, p. 445-459.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Mining the fecal proteome

T2 - from biomarkers to personalised medicine

AU - Jin, Ping

AU - Wang, Kui

AU - Huang, Canhua

AU - Nice, Edouard C.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Fecal proteomics has gained increased prominence in recent years. It can provide insights into the diagnosis and surveillance of many bowel diseases by both identifying potential biomarkers in stool samples and helping identify disease-related pathways. Fecal proteomics has already shown its potential for the discovery and validation of biomarkers for colorectal cancer screening, and the analysis of fecal microbiota by MALDI-MS for the diagnosis of a range of bowel diseases is gaining clinical acceptance. Areas covered: Based on a comprehensive analysis of the current literature, we introduce the range of sensitive and specific proteomics methods which comprise the current ‘Proteomics Toolbox’, explain how the integration of fecal proteomics with data processing/bioinformatics has been used for the identification of potential biomarkers for both CRC and other gut-related pathologies and analysis of the fecal microbiome, outline some of the current fecal assays in current clinical practice and introduce the concept of personalised medicine which these technologies will help inform. Expert commentary: Integration of fecal proteomics with other proteomics and genomics strategies as well as bioinformatics is paving the way towards personalised medicine, which will bring with it improved global healthcare.

AB - Introduction: Fecal proteomics has gained increased prominence in recent years. It can provide insights into the diagnosis and surveillance of many bowel diseases by both identifying potential biomarkers in stool samples and helping identify disease-related pathways. Fecal proteomics has already shown its potential for the discovery and validation of biomarkers for colorectal cancer screening, and the analysis of fecal microbiota by MALDI-MS for the diagnosis of a range of bowel diseases is gaining clinical acceptance. Areas covered: Based on a comprehensive analysis of the current literature, we introduce the range of sensitive and specific proteomics methods which comprise the current ‘Proteomics Toolbox’, explain how the integration of fecal proteomics with data processing/bioinformatics has been used for the identification of potential biomarkers for both CRC and other gut-related pathologies and analysis of the fecal microbiome, outline some of the current fecal assays in current clinical practice and introduce the concept of personalised medicine which these technologies will help inform. Expert commentary: Integration of fecal proteomics with other proteomics and genomics strategies as well as bioinformatics is paving the way towards personalised medicine, which will bring with it improved global healthcare.

KW - big data

KW - Biomarkers

KW - colorectal cancer

KW - fecal proteomics

KW - HUPO

KW - mass spectrometry

KW - microbiota

KW - personalised medicine

UR - http://www.scopus.com/inward/record.url?scp=85019037081&partnerID=8YFLogxK

U2 - 10.1080/14789450.2017.1314786

DO - 10.1080/14789450.2017.1314786

M3 - Review Article

VL - 14

SP - 445

EP - 459

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 5

ER -